Inhibition of pre-existing natural periodontitis in non-human primates by a locally administered peptide inhibitor of complement C3


Abstract

Aim: Human periodontitis is associated with overactivation of complement, which is triggered by different mechanisms converging on C3, the central hub of the system. We assessed whether the C3 inhibitor Cp40 inhibits naturally occurring periodontitis in non-human primates (NHPs).

Materials and Methods: Non-human primates with chronic periodontitis were intra-gingivally injected with Cp40 either once (5 animals) or three times (10 animals) weekly for 6 weeks followed by a 6-week follow-up period. Clinical periodontal examinations and collection of gingival crevicular fluid and biopsies of gingiva and bone were performed at baseline and during the study. A one-way repeated-measures ANOVA was used for data analysis.

Results: Whether administered once or three times weekly, Cp40 caused a significant reduction in clinical indices that measure periodontal inflammation (gingival index and bleeding on probing), tissue destruction (probing pocket depth and clinical attachment level) or tooth mobility. These clinical changes were associated with significantly reduced levels of pro-inflammatory mediators and decreased numbers of osteoclasts in bone biopsies. The protective effects of Cp40 persisted, albeit at reduced efficacy, for at least 6 weeks following drug discontinuation.

Conclusion: Cp40 inhibits pre-existing chronic periodontal inflammation and osteoclastogenesis in NHPs, suggesting a novel adjunctive anti-inflammatory therapy for treating human periodontitis.

Key words: complement; compstatin; cytokines; inflammation; non-human primates; periodontitis

Conflict of interest and source of funding statement

G.H. and J.D.L. have a joint patent application that describes the use of complement inhibitors for therapeutic purposes in periodontitis. J.D.L. is the founder of Amyndas Pharmaceuticals, which is developing complement inhibitors for clinical applications. This work was supported by grants from the National Institutes of Health (AI068730 and AI030040 to J.D.L.; DE015254, DE017138, DE021685 and DE024716 to G.H.) and the European Commission (FP7-DIREKT 602699 to J.D.L.).
Periodontitis is a prevalent chronic oral disease that affects nearly half of adults in the USA and the UK and perhaps worldwide (Demmer & Papapanou 2010, White et al. 2012, Eke et al. 2015). The disease is driven by exaggerated inflammation induced by dysbiotic microbial communities forming on subgingival tooth sites (Lamont & Hajishengallis 2015) and can lead to tooth loss and impaired mastication and nutritional status (Chapple 2014). Tooth loss may occur as a result of excessive destruction of periodontium. In its severe form that affects almost 10% of adults (Eke et al. 2012, White et al. 2012), chronic periodontitis is not merely a common cause of tooth loss, but is also associated with certain systemic conditions, such as atherosclerosis, diabetes, rheumatoid arthritis, chronic obstructive pulmonary disease and adverse pregnancy outcomes (Tonetti et al. 2007, Kebischull et al. 2010, Lalla & Papapanou 2011, Han et al. 2014, Koziel et al. 2014, Hajishengallis 2015). The serious public health impact of this oral disease and its economic burden (Beikler & Flemmig 2011, Chapple 2014) call for innovative treatments adjunctive to existing therapies (such as mechanical removal of the tooth-associated biofilm and antimicrobial treatment), which are not always sufficient to control periodontitis (Armitage 2002, Colombo et al. 2012, Rams et al. 2014). In this study, we have tested a complement-targeted therapeutic approach in a highly relevant preclinical model of periodontitis.

The complement system, a network of interacting fluid-phase and cell surface-associated molecules, is centrally involved in immunity and inflammation through direct effects on immune cells or crosstalk and regulation of other host signalling pathways, such as those activated by toll-like receptors (TLRs) (Hajishengallis & Lambris 2010). The various components of complement are produced systemically or locally in peripheral tissues and the system can be triggered via distinct cascade mechanisms (classical, lectin or alternative), all of which converge at the third component (C3) (Ricklin et al. 2010). C3 cleavage and activation by convertases leads to the generation of effector molecules that mediate diverse functions, including recruitment and activation of inflammatory cells (induced by the anaphylatoxins C3a and C5a), microbial opsonization and phagocytosis (via opsonins such as C4b and C3b) and direct lysis of susceptible microbes (by the C5b-9 membrane attack complex) (Ricklin et al. 2010).


More recently, studies in animal models, including mouse strains with complement knockout mutations, have established a cause-and-effect relationship between complement activation and periodontitis and gleaned insights into the mechanisms whereby complement mediates periodontitis (Breivik et al. 2011, Hajishengallis et al. 2011, Liang et al. 2011, Maekawa et al. 2014a, b). In this regard, we have shown that C3-dependent inflammation in mice is crucial for the long-term sustenance of the dysbiotic microbiota and for maximal induction of alveolar bone loss (Maekawa et al. 2014a). Consistent with these findings, local C3 inhibition in a model of ligature-induced periodontitis in young non-human primates (NHPs) prevents the development of gingival inflammation and alveolar bone loss (Maekawa et al. 2014a). The inhibitor we used was Cp40, an improved analogue of compstatin, which is a peptidic compound that blocks C3 activation exclusively in humans and non-human primates (Qu et al. 2013, Ricklin & Lambris 2013, Mastellos et al. 2015b). Cp40 and other compstatin analogues bind C3 and interfere with its binding to and cleavage by the C3 convertase, thereby blocking the generation of downstream effector molecules regardless of the initiation pathway of complement activation (Ricklin & Lambris 2013, Mastellos et al. 2015b).

However, whether Cp40 is effective in a therapeutic – rather than preventive – setting was not addressed in our previous publication. The main objective of this study was therefore to determine whether local C3 inhibition could inhibit pre-existing chronic periodontal disease, which typically affects adults; in this context, ageing is thought to affect the immuno-inflammatory status of the periodontal tissue, thereby contributing to increased susceptibility to periodontitis (Hajishengallis 2014a). This notion is consistent with recent studies in NHPs showing age-dependent differential expression of immune and inflammatory genes in the periodontium (Ebersole et al. 2015, Gonzalez et al. 2015). By screening a population of adult NHPs (cynomolgus monkeys) in the Simian Conservation Breeding and Research Center (SICONBREC, Makati, Philippines), we identified animals with naturally occurring chronic periodontitis and treated them with Cp40. Our results show that locally administered Cp40 can reverse pre-existing chronic periodontal inflammation in the absence of additional treatments, such as scaling and root planing, thus identifying an anti-inflammatory therapy that can potentially contribute to the treatment of human periodontitis.

Materials and Methods

Non-human primates

All animal procedures were performed according to protocols reviewed and approved by the Institutional Animal Care and Use Committees of the University of Pennsylvania and of the SICONBREC, an Association for Assessment and Accreditation of
Laboratory Animal Care Internationally-accredited facility where the NHP work was performed. Fifteen adult male cynomolgus monkeys (Macaca fascicularis) (7–15 years old; 5.0–7.6 kg body weight) were selected for the study after screening the SICONBREC breeding colonies for animals with chronic periodontitis. The inclusion criteria were the presence of at least 30% of sites with probing pocket depth and clinical attachment level ≥4 mm, associated with bleeding on probing, and radiographic evidence of bone loss (using a digital X-ray dental system; Vatech, Fort Lee, NJ, USA). The animals were socially housed in stainless steel cages and were used in the study after they were acclimatized to the protocol procedures for 4 weeks. Environmental enrichment was provided through daily handling by animal care technicians, environmental enrichment items and visual contact with other study animals. Each animal was offered a measured amount of an approved feed mixture. Fresh, potable drinking water was available to the animals ad libitum. Clinical periodontal examinations, dental X-rays, collection of GCF and periodontal tissue biopsies were performed in a manner similar to a human clinical study, except that the animals were anaesthetized during the procedures.

C3 inhibitor

The compstatin analogue Cp40 (y-I-[CV(1MeW)QDW-Sar-AHRC(NMeI)]-NH₂; with y = D-tyrosine; Sar = sarcosine/N-methyl glycine) was produced as a disulphide-bridged, cyclic peptide by solid-phase peptide synthesis methodology as previously described (Qu et al. 2013).

Experimental design

The study involved a 6-week treatment period with Cp40 and a 6-week follow-up period without Cp40 treatment. Cp40 was administered either once a week (5 animals; “1x-treatment”) or three times per week (10 animals; “3x-treatment”). Specifically, using a 30-g short needle, Cp40 was injected locally into the gingiva (100 μg/site in 50-μl volume) of anterior and posterior teeth on both sides of the maxilla (15 sites total; 13 sites corresponding to palatal inter-dental papillae and two sites corresponding to the distal gingiva of the second molars). Clinical readings made before Cp40 administration served as baseline controls for each animal. The mandible was not treated with Cp40 but was monitored by clinical periodontal examination and sampling of biological specimens (see below) throughout the study, for comparative purposes. Clinical examinations, sample collection and standard laboratory techniques (immunofluorescence histochemistry, histological TRAP staining and assessment of host immune responses) are described in Appendix S1.

Statistical analysis

For the comparison of mean values within the groups during the time-course studies, one-way repeated-measures ANOVA with Greenhouse-Geisser correction was performed using the GraphPad Prism program, version 6.0h (La Jolla, CA, USA). In case of significant differences, Bonferroni’s or Tukey’s multiple comparisons test was performed.

Results

Locally administered Cp40 inhibits clinical periodontal inflammation in NHPs

All animals enrolled in the study were systemically healthy and maintained good systemic health during the observation period. No adverse effects were noted during the course of the study. To determine whether complement is causally linked to inflammation associated with naturally occurring chronic periodontitis, we targeted the central complement component C3. Specifically, we locally injected the C3-specific inhibitor Cp40 into the maxillary gingiva of NHPs. Initially, the drug was administered for 6 weeks at a frequency of three times weekly (“3x-treatment”) and its clinical effects were monitored for 12 weeks. Cp40 caused a significant reduction in several clinical indices that measure periodontal inflammation (gingival index and bleeding on probing), tissue destruction (probing pocket depth and clinical attachment level) or tooth mobility often associated with bone loss (Fig. 1a–e). These data indicate that, at least by clinical criteria, Cp40 blocks inflammatory processes that drive periodontal tissue destruction. Interestingly, these protective effects were evident as early as 1 week after treatment initiation and progressively improved until week 6, when the drug was discontinued. Remarkably, the protective effects of Cp40 persisted for at least six additional weeks, since at the termination of the study (week 12) all indices remained at significantly lower levels relative to their corresponding baselines (Fig. 1a–e). Importantly, without any exception, all ten cynomolgus monkeys responded favourably to Cp40 with 57–87% reduction in gingival inflammation and 31–58% decrease in the depths of the periodontal pockets after 6 weeks of treatment (Figs S1–S10). The plaque index, a clinical measure of biofilm accumulation on tooth surfaces, was modestly but significantly reduced by Cp40 at a few time points, immediately before and after week 6 (Fig. 1f). The aforementioned clinical indices were also monitored in the untreated jaw (mandible) during the same 12-week interval. In contrast to the improved clinical condition of the Cp40-treated maxilla, the clinical indices in the mandible did not show significant differences in the course of the study as compared to their baseline values (Fig. 1a–f).

In a second, independent experiment, we investigated whether Cp40 could retain its efficacy if administered only once per week (“1x-treatment”). Similar clinical analyses revealed that a single weekly administration of Cp40 could significantly reduce indices of clinical inflammation and tissue destruction (Fig. 2), with almost comparable efficacy and similar time course pattern to that of the 3x-treatment (see superimposition of the data in Fig. S11). Moreover, similar to the 3x-treatment, all five cynomolgus monkeys used in the 1x-treatment study responded favourably to the drug with no exception (Figs S12–S16).

Decreased levels of pro-inflammatory mediators following local treatment with Cp40

GCF was collected for monitoring changes in the cytokine and immune
mediator levels during the 6-week course of Cp40 treatments, as well as during the follow-up period to week 12. Multi-cytokine analysis of the GCF revealed that the 3x treatment with Cp40 resulted in significantly lower levels of pro-inflammatory and osteoclastogenic cytokines, as compared to their baseline values (Fig. 3). The pro-inflammatory cytokines measured included IL-1β, IL-6, IL-8 and IL-17 (Fig. 3a–d), all of which have been associated with periodontal inflammation in humans (Graves 2008, Moutsopoulos et al. 2012, Zenobia & Hajishengalis 2015), and receptor activator of NF-κB ligand (RANKL) (Fig. 3e), a key osteoclastogenic cytokine involved in bone loss disorders including periodontitis (Bostanci et al. 2007, Miossec & Kolls 2012). In contrast, the GCF levels of osteoprotegerin (OPG), a natural antagonist of RANKL (Bostanci et al. 2007, Miossec & Kolls 2012), were increased upon Cp40 treatment relative to baseline (Fig. 3f). Cp40 also caused a significant decrease in the GCF levels of C3a and C5/C5a as seen as early as 1 week after treatment (Fig. 3g,h respectively). These favourable changes in the host response profile (inhibition of pro-inflammatory mediators and upregulation of OPG) were most pronounced at 6 weeks, although significant changes persisted for the entire or most of the study duration (12 weeks), despite drug withdrawal at week 6 (Fig. 3). The same mediators were monitored in GCF samples collected from the untreated jaw (mandible) during the same 12-week interval but did not show significant differences relative to baseline values (Fig. 3). Importantly, Cp40 retained its capacity to significantly suppress the GCF levels of pro-inflammatory mediators and upregulate OPG even when administered only once per week (Fig. 4).

The anti-inflammatory action of Cp40 was also evident in the periodontal tissue (Fig. 5), thus confirming the GCF findings. Specifically, immunofluorescence histochemistry of biopsy specimens taken before (0 week) and after (6 weeks) treatment showed that Cp40 caused decreased expression of IL-17, RANKL and elevated expression of OPG in the connective tissue adjacent to the alveolar bone at 6 weeks relative to baseline (Fig. 5). Moreover, Cp40 treatment caused a decrease in the complement cleavage fragments C3d and C5a (Fig. 5), further confirming its ability to inhibit complement activation.

The inhibitory action of Cp40 on the various pro-inflammatory and/or pro-osteoclastogenic cytokines was mediated, at least in part, at the transcriptional level since the expression of gingival IL-1β, IL-6, IL-8, IL-17 and RANKL mRNA was significantly inhibited in animals with 3x or 1x weekly treatments (Fig. 6). Conversely, and in accord with the protein data, OPG mRNA expression was increased (Fig. 6). The characteristic elevation of IL-1β in human periodontitis (compared to periodontal health) has been correlated with increased NLRP3 (NALP3) inflammasome mRNA expression levels (Bostanci et al. 2009). In this regard, Cp40 inhibited the gingival NLRP3 mRNA expression in NHPs (Fig. 6), suggesting its potential to interfere with NLRP3 inflammasome-dependent processing of IL-1β; this notion is consistent with the reduced levels...
of IL-1β protein in the GCF of Cp40-treated animals (Figs 3a and 4a).

Cp40 causes a reduction in the numbers of periodontal osteoclasts in NHPs

The RANKL/OPG ratio in the GCF is a potential indicator of periodontitis (Bostanci et al. 2007, Belibasakis & Bostanci 2012). We therefore determined whether the ability of Cp40 to decrease the GCF levels of RANKL and enhance the levels of OPG (Figs 3 and 4), hence to lower the RANKL/OPG ratio, could have an impact on osteoclastogenesis. To this end, we counted the numbers of osteoclasts (TRAP-positive multinucleated cells; Fig. S17) in bone biopsies taken at baseline and at 6 and 12 weeks following Cp40 treatment. We found that in the maxillae of the animals, Cp40 caused a significant decrease in the numbers of osteoclasts after 6 weeks of 3× or 1× weekly treatments (Fig. 7a,b, left panels). This favourable effect persisted through to week 12, even though the drug was not administered in the last 6 weeks (Fig. 7a,b, left panels). In contrast, the numbers of osteoclasts in the mandibles, which were not treated, did not display significant differences in the course of the study (Fig. 7a,b, right panels).

Discussion

To the best of our knowledge, this study marks the first time that a pharmacological intervention – whether host-modulation or antimicrobial – is shown to inhibit inflammation in the context of naturally occurring periodontitis in NHPs. Previously conducted studies, including our own, have used inducible models of the disease involving placement of ligatures with or without exogenous inoculation of periodontal pathogens (Offenbacher et al. 1987, Pierce & Lindskog 1987, Nisengard et al. 1989, Persson et al. 1994, Li et al. 1996, Assuma et al. 1998, Moritz et al. 1998, Cappelli et al. 2000, Roberts et al. 2004, Page et al. 2007, Maekawa et al. 2014a, Shin et al. 2015). The immune system and periodontal anatomy of the cynomolgus monkey is similar to that of humans, and periodontitis in these animals exhibits clinical, microbiological and immuno-histological features that are highly similar to those observed in human periodontitis (Kornman et al. 1981, Page & Schroeder 1982, Brecx et al. 1985, Ebersole et al. 2002, 2014). Therefore, the cynomolgus model, especially in the setting of naturally occurring periodontitis, is considerably more predictive of drug efficacy in humans compared to widely used models, such as those in rodents, rabbits or dogs. The successful Cp40 inhibition of natural periodontal inflammation and osteoclastogenesis in NHPs additionally shows unequivocally that C3 is critical for the pathogenesis of this oral disease, as suggested by earlier correlative human clinical studies (Attstrom et al. 1975, Schenkein & Genco 1977, Toto et al. 1978, Niekrash & Patters 1985, Nikolopoulou-Papconstantinou et al. 1987, Patters et al. 1989, Hajishengallis 2010). In conjunction with the earlier human studies, the present work places periodontitis to a growing list of diseases with substantial complement involvement, including paroxysmal nocturnal haemoglobinuria (PNH),...
age-related macular degeneration, atypical haemolytic uraemic syndrome and rheumatoid arthritis (Ricklin & Lambris 2013). Consistent with the role of C3 as a potential therapeutic target in periodontitis, a recent report has identified C3 among the top 21 most promising candidate genes involved in periodontitis, by using an integrative gene prioritization method and databases from genome-wide association studies and microarray experiments (Zhan et al. 2014).

The complement inhibition capacity of Cp40 was confirmed by findings of decreased GCF levels of C3a and C5/C5a. The detecting antibody utilized in the latter assay does not distinguish between C5 and the activation product C5a and, therefore, C5 levels could be reduced indirectly by Cp40 through inhibition of inflammation (Zou et al. 2013). However, the ability of Cp40 to reduce C3a definitely confirmed its potential to inhibit complement activation in our study. In this regard, it is uncertain if intra-gingivally administered Cp40 inhibited complement activation in the gingival tissue resulting in lower levels of available C3a to transudate to the periodontal pocket or whether Cp40 also diffused to the periodontal pocket where it could additionally block complement activation in the GCF. Although both possibilities are likely, the ability of Cp40 to block complement in the gingiva was confirmed by immunohistochemistry that showed decreased levels of the complement cleavage products (C3d and C5a) in the connective tissue in the vicinity of the bone.

Cp40 is the first compstatin analogue with subnanomolar target affinity (KD = 0.5 nM) and features a plasma half-life that exceeds expectations for most peptidic drugs (Qu et al. 2013, Mastellos et al. 2015b). The relatively long half-life of the Cp40 peptide was attributed to a “target-driven” model, according to which an initial rapid clearance of excess free peptide (i.e. not bound to C3) is followed by slow clearance of C3-bound peptide. As the measured half-life values of different compstatin analogues correlate positively with their binding affinities for C3 (Qu et al. 2013), it can be inferred that the tight binding of Cp40 to C3

Fig. 3. Decreased GCF levels of pro-inflammatory and pro-osteoclastogenic mediators in NHPs with natural periodontitis after local treatment with Cp40 three times weekly. At the indicated time points, GCF was collected from monkeys with natural periodontitis which were treated three times weekly for 6 weeks with Cp40 in the maxilla (“Cp40”) but not in the mandible (“Untreated”). Total cytokine or mediator content (a, IL-1β; b, IL-6; c, IL-8; d, IL-17; e, RANKL; f, osteoprotegerin (OPG); g, C3a; h, C5/C5a) in the eluted GCF samples was measured using a Bio-Plex system or ELISA (C3a only). Data are means ± SD (n = 10 monkeys). *p < 0.05; **p < 0.01 compared to baseline (one-way repeated-measures ANOVA and Bonferroni’s multiple comparisons test). GCF, gingival crevicular fluid; NHPs, non-human primates; OPG, osteoprotegerin; RANKL, receptor activator of NF-κB ligand.
delays its clearance. Similarly, the expected tight binding of Cp40 to abundant C3 in the inflamed periodontium could contribute to delayed elimination of the drug from the tissues, in turn accounting—at least in part—for the sustained protective effect of Cp40 observed in this study. Alternatively, or additionally, it is likely that the observed suppression of inflammation by Cp40 tips the balance towards tissue homeostasis, which might then resist pathological processes for some time even in the absence of the drug. In this regard, the clinical periodontal indices, the GCF levels of pro-inflammatory mediators and the numbers of periodontal osteoclasts persisted at lower levels than their corresponding baseline values for at least 6 weeks following drug withdrawal.

Given that complement is not a linear cascade of events but essentially a hub-like network that is tightly connected to other components of the immune system (Ricklin et al. 2010), it is plausible that C3 inhibition has a far-reaching impact above and beyond complement itself. For instance C3a- and C5a-induced signalling pathways cross-talk with and amplify TLR-mediated inflammatory responses in various tissues including the periodontium (Zhang et al. 2007, Hajishengallis & Lambris 2010, Abe et al. 2012). Complement inhibition, therefore, is likely to mitigate inflammation initiated through TLR activation, either by microbial ligands (e.g. bacterial lipopolysaccharide or lipoproteins) or by endogenous molecules acting as danger signals upon their release due to inflammatory tissue destruction (e.g. biglycan, hyaluronan fragments and heparan sulphate fragments) (Miyake 2007, Schaefer 2010). These considerations may in part explain why the inhibition of a single molecule, C3, has a strong influence on the course of natural periodontal inflammation.

It was also recently shown that, in human monocytes, C3a regulates the release of intracellular ATP into the extracellular space, thereby controlling NLRP3 inflammasome activation and subsequent secretion of IL-1β, which in turn promotes human CD4+ T cell production of IL-17 (Asgari et al. 2013). In this regard, a clinical study has shown enhanced expression of NLRP3

---

**Fig. 4.** Single weekly administration of Cp40 decreases the levels of pro-inflammatory and pro-osteoclastogenic mediators in the GCF of NHPs with natural periodontitis. At the indicated time points, GCF was collected from monkeys with natural periodontitis which were treated once weekly for 6 weeks with Cp40 in the maxilla (“Cp40”) but not in the mandible (“Untreated”). Total cytokine or mediator content (a, IL-1β; b, IL-6; c, IL-8; d, IL-17; e, RANKL; f, OPG; g, C3a; h, C5/C5a) in the eluted GCF samples was measured using a Bio-Plex system or ELISA (C3a only). Data are means ± SD (n = 5 monkeys). *p < 0.05; **p < 0.01 compared to baseline (one-way repeated-measures ANOVA and Bonferroni’s multiple comparisons test). GCF, gingival crevicular fluid; NHPs, non-human primates; OPG, osteoprotegerin; RANKL, receptor activator of NF-κB ligand.
NALP3 inflammasome in periodontitis correlating with increased IL-1β expression levels (Bostanci et al. 2009). Moreover, the formation of sublytic C5b-9 complex on human epithelial cells induces intracellular Ca²⁺ fluxes leading to NLRP3 inflammasome activation and IL-1β release (Triantafilou et al. 2013). Both of these complement-dependent inflammatory mechanisms can be blocked by Cp40, potentially accounting — at least in part — for the reduced IL-1β and IL-17 levels after Cp40 treatment. In fact, the ability of Cp40 to reduce the levels of IL-1β protein in the GCF might, in part, be related to its capacity to inhibit the expression of NLRP3 which is involved in caspase-1–mediated processing and release of IL-1β protein (Lamkanfi & Dixit 2014).

Cp40-mediated inhibition of IL-17 could in turn contribute to the observed suppression of RANKL, since IL-17 upregulates RANKL by acting on lymphocytes and stromal cells (e.g. fibroblasts and osteoblasts) (Miossec & Kolls 2012). Besides inhibiting RANKL expression, Cp40 also caused a concomitant increase in the levels of OPG, both in the gingival tissue and the GCF. Although the underlying mechanisms are uncertain, RANKL and OPG were shown to be conversely regulated by several stimuli (Lee & Lorenzo 1999, Devi et al. 2013, Boespflug et al. 2014). For instance IL-17 was shown to induce RANKL and suppress OPG expression in human periodontal

© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
Consequently, the ability of Cp40 to decrease the RANKL/OPG ratio was associated with decreased osteoclastogenesis in bone biopsy samples. Therefore, Cp40 has the potential to inhibit naturally occurring bone loss, in accord with its capacity to block ligature-induced bone loss in NHPs (Maekawa et al. 2014a). Although induction of measurable bone loss can be observed within a few weeks in the relatively acute ligature-induced model, bone loss is a relatively slow process in naturally occurring chronic periodontitis (hence changes in bone loss could not be detected radiographically in this study due to its relatively short duration).

By inhibiting complement at the level of C3, Cp40 (and earlier compstatin analogues) does not interfere with C4b-mediated opsonization of bacteria via the classical and lectin pathways (Kirjavainen et al. 2008). Nevertheless, for increased safety, Cp40 treatments in disease settings requiring long-term systemic intervention (e.g. in PNH (Risitano et al. 2014)) would necessitate vaccination against encapsulated bacteria (e.g. meningococci) to minimize the risk of potential infections (Mastellos et al. 2015a). Importantly, these potential safety considerations are unlikely to apply to the treatment of periodontitis through local Cp40 administration. In this regard, C3-deficient mice display reduced periodontal bacterial load compared to C3-sufficient controls in the course of experimental periodontitis (Maekawa et al. 2014a), suggesting that impaired complement activation does not predispose to defective immune surveillance in the periodontium. These findings are in accord with the notion that inflammation generates tissue breakdown products (e.g. degraded collagen peptides or haeme-containing compounds) that serve the nutritional needs of periodontitis-associated bacteria (Marsh 2003, Hajishengallis 2014b). Indeed, studies in mouse and rabbit models of periodontitis indicate that the control of inflammation also reduces the bacterial load (Hasturk et al. 2007, Eskan et al. 2012, Abe et al. 2014, Moutsopoulos et al. 2014). Conversely, and consistently, the bacterial biomass of human periodontitis-associated biofilms increases with escalating periodontal inflammation (Abusleme et al. 2013).

Although Cp40 was successfully applied as a stand-alone treatment in the current NHP study, it can be envisioned as an adjunctive therapy to the management of human chronic periodontitis. Future clinical trials could investigate the potential of Cp40 to inhibit periodontal inflammation and bone loss compared to scaling and root planing, whereas in very severe cases of the disease, Cp40 could be combined with scaling and root planing and compared to periodontal surgery, in an effort to obviate the need for a surgical approach. It should be noted that future host-modulation interventions, such as Cp40, would not necessarily be implemented in a therapeutic setting but could also be provided on a preventive basis to high-risk individuals, such as cigarette smokers and diabetic patients (Heitz-Mayfield 2005, Genco & Genco 2014), before the onset of periodontitis. A clinically developed Cp40-based drug (AMY-101; Amyndas Pharmaceuticals, Glyfada, Attica, Greece.) is currently under evaluation as a potential treatment of complications of ABO-incompatible kidney transplantation and PNH (Mastellos et al. 2015b). Whether Cp40/AMY-101 can find application for the treatment of human periodontitis is a possibility that – based on the results of this NHP study – merits investigation in future clinical trials.

Acknowledgements

We thank Dr. Niki M. Moutsopoulos (NIDCR/NIH) for comments and suggestions.


**Supporting Information**

Additional Supporting Information may be found in the online version of this article:

**Appendix S1.** Supplementary methods.

**Figure S1.** Effects of Cp40 on inflammatory clinical parameters of NHP chronic periodontitis (3× treatment): Raw data for monkey #1.

**Figure S2.** Effects of Cp40 on inflammatory clinical parameters of NHP chronic periodontitis (3× treatment): Raw data for monkey #2.

**Figure S3.** Effects of Cp40 on inflammatory clinical parameters of NHP chronic periodontitis (3× treatment): Raw data for monkey #3.

**Figure S4.** Effects of Cp40 on inflammatory clinical parameters of NHP chronic periodontitis (3× treatment): Raw data for monkey #4.

**Figure S5.** Effects of Cp40 on inflammatory clinical parameters of NHP chronic periodontitis (3× treatment): Raw data for monkey #5.

**Figure S6.** Effects of Cp40 on inflammatory clinical parameters of NHP chronic periodontitis (3× treatment): Raw data for monkey #6.

**Figure S7.** Effects of Cp40 on inflammatory clinical parameters of NHP chronic periodontitis (3× treatment): Raw data for monkey #7.

**Figure S8.** Effects of Cp40 on inflammatory clinical parameters of NHP chronic periodontitis (3× treatment): Raw data for monkey #8.

**Figure S9.** Effects of Cp40 on inflammatory clinical parameters of NHP chronic periodontitis (3× treatment): Raw data for monkey #9.

**Figure S10.** Effects of Cp40 on inflammatory clinical parameters of NHP chronic periodontitis (3× treatment): Raw data for monkey #10.

**Figure S11.** Cp40 decreases inflammatory clinical parameters of naturally occurring chronic periodontitis in NHPs.

**Figure S12.** Effects of Cp40 on inflammatory clinical parameters of NHP chronic periodontitis (1× treatment): Raw data for monkey #1.

**Figure S13.** Effects of Cp40 on inflammatory clinical parameters of NHP chronic periodontitis (1× treatment): Raw data for monkey #2.

**Figure S14.** Effects of Cp40 on inflammatory clinical parameters of NHP chronic periodontitis (1× treatment): Raw data for monkey #3.

**Figure S15.** Effects of Cp40 on inflammatory clinical parameters of NHP chronic periodontitis (1× treatment): Raw data for monkey #4.

**Figure S16.** Effects of Cp40 on inflammatory clinical parameters of NHP chronic periodontitis (1× treatment): Raw data for monkey #5.

**Figure S17.** Detection of osteoclasts in non-human primate periodontitis.

**Clinical Relevance**

**Scientific rationale for the study:** Most interventional studies in animal models of periodontitis are performed in a preventive (rather than therapeutic) setting and involve inducible models of the disease. To increase the predictive value of preclinical intervention for drug efficacy in humans, we used non-human primates with naturally occurring periodontitis to test the therapeutic potential of a complement inhibitor (Cp40).

**Principal findings:** Cp40 inhibited pre-existing periodontal inflammation (determined by both clinical and laboratory assessment) and osteoclastogenesis in non-human primates, a clinically relevant model of human periodontitis.

**Practical implications:** These findings pave the way for testing Cp40 in future clinical trials for the treatment of human periodontitis.